User contributions for Alara E. Dagsali

Jump to navigation Jump to search
Search for contributionsExpandCollapse
⧼contribs-top⧽
⧼contribs-date⧽
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

16 May 2024

  • 07:0707:07, 16 May 2024 diff hist +21‎ User:AED ‎No edit summary current
  • 07:0607:06, 16 May 2024 diff hist +3‎ Diclofenac Patch ‎No edit summary current
  • 07:0607:06, 16 May 2024 diff hist +48,610‎ N Diclofenac Patch ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr..."
  • 06:4206:42, 16 May 2024 diff hist +24‎ User:AED ‎No edit summary
  • 06:4206:42, 16 May 2024 diff hist +3‎ Cortisone Acetate ‎No edit summary current
  • 06:4206:42, 16 May 2024 diff hist +14,095‎ N Cortisone Acetate ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen..."
  • 06:3306:33, 16 May 2024 diff hist +27‎ User:AED ‎No edit summary
  • 06:3306:33, 16 May 2024 diff hist +3‎ Clocortolone Pivalate ‎No edit summary current
  • 06:3206:32, 16 May 2024 diff hist +4,443‎ N Clocortolone Pivalate ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed..."
  • 06:2206:22, 16 May 2024 diff hist +30‎ User:AED ‎No edit summary
  • 06:2106:21, 16 May 2024 diff hist +30‎ Scorpion ‎No edit summary current
  • 06:2006:20, 16 May 2024 diff hist +12,418‎ N Scorpion ‎ Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u..."

15 May 2024

  • 10:5910:59, 15 May 2024 diff hist +3‎ Lodoxamide ‎No edit summary current
  • 10:5810:58, 15 May 2024 diff hist +6,534‎ N Lodoxamide ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve..."

30 April 2024

  • 18:5818:58, 30 April 2024 diff hist +20‎ User:AED ‎No edit summary
  • 18:5818:58, 30 April 2024 diff hist +3‎ Isosulfan Blue ‎No edit summary current
  • 18:5718:57, 30 April 2024 diff hist +5,959‎ N Isosulfan Blue ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape..."
  • 18:4718:47, 30 April 2024 diff hist +22‎ User:AED ‎No edit summary
  • 18:4718:47, 30 April 2024 diff hist +3‎ Ibuprofen Lysine ‎No edit summary current
  • 18:4618:46, 30 April 2024 diff hist +15,663‎ N Ibuprofen Lysine ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc..."
  • 18:2818:28, 30 April 2024 diff hist +20‎ User:AED ‎No edit summary
  • 18:2818:28, 30 April 2024 diff hist +3‎ Prussian blue ‎No edit summary current
  • 18:2718:27, 30 April 2024 diff hist +14,067‎ N Prussian blue ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R..."
  • 18:1518:15, 30 April 2024 diff hist +23‎ User:AED ‎No edit summary
  • 18:1518:15, 30 April 2024 diff hist +3‎ Botulism Antitoxin ‎No edit summary current
  • 18:1418:14, 30 April 2024 diff hist +18,008‎ N Botulism Antitoxin ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse..."

29 April 2024

  • 15:2615:26, 29 April 2024 diff hist +27‎ User:AED ‎No edit summary
  • 15:2515:25, 29 April 2024 diff hist −35‎ Trastuzumab emtansine ‎No edit summary current
  • 15:2315:23, 29 April 2024 diff hist +40,610‎ N Trastuzumab emtansine ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment..."

25 April 2024

24 April 2024

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)
Retrieved from "https://www.wikidoc.org/index.php/Special:Contributions/Alara_E._Dagsali"